Company intelligence / Profile preview
Pieris Pharmaceuticals
Boston, MA, USApieris.com ↗
- Ownership
- Public · PIRS
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Pieris Pharmaceuticals was a clinical-stage biotechnology company developing novel protein therapeutics using its proprietary Anticalin® platform. Its lead programs targeted respiratory and oncology indications, with several assets partnered with major pharmaceutical companies. In December 2024, it merged with Palvella Therapeutics; future development of its pipeline will depend on the new parent company's strategy.
- Therapeutic areas
- OtherOncologyPulmonology
- Modalities
- Anticalin proteins (proprietary protein therapeutics platform)Bispecific antibodiesProtein-based drugs
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
03
Partnerships
AstraZeneca PlcBoston PharmaceuticalsServier SASGenentechSeattle Genetics Inc./Pfizer
Beyond the preview
Go deeper on Pieris Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pieris Pharmaceuticals.